Acute vasoreactivity testing for severe pulmonary hypertension associated with lung disease

31 August 2024 (17:00 - 17:50)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Ryo Takano

National Cerebral & Cardiovascular Center, Suita (Japan)

7 More presentations in this session

Presentation thumbnail

Comparison of pulmonary arterial risk assessment tools to predict mortality or morbidity in treatment naive and previously diagnosed patients.

Doctor C. Fauvel (Rouen, FR)

Abstract Slides Video

Presentation thumbnail

Prognostic value of follow-up hemodynamics after initial treatment in pulmonary arterial hypertension

Doctor D. Guarino (Bologna, IT)

Abstract Slides Video

Presentation thumbnail

Multiparametric risk predictions for morbidity and mortality in patients with pulmonary arterial hypertension: insights from a nation-wide registry

Professor C. Kaymaz (Istanbul, TR)

Abstract Slides Video

Presentation thumbnail

Health care utilisation in patients with mild pulmonary hypertension - EVIDENCE-PAH UK study

Doctor N. Karia (London, GB)

Abstract Slides Video

Presentation thumbnail

Does the presence of severe pulmonary hypertension affect survival at 5 years follow-up in patients who underwent TAVI for severe aortic stenosis?

Doctor H. Mohiaddin (Leicester, GB)

Abstract Slides Video

Access the full session

Session thumbnail

Impact of pulmonary hypertension on quality of life and survival

The Event

Event poster

ESC Congress 2024

31 August 2024 17:00 CET

You may be interested in

Congress Session

Diagnosis and therapy of chronic thromboembolic pulmonary hypertension

Congress Session

Molecular approaches to the treatment of pulmonary hypertension

Congress Session

Paradigm change in pulmonary hypertension: from bench to bedside

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources